F. Silvestri et al., Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation, BR J HAEM, 108(2), 2000, pp. 394-396
Reactivation of hepatitis B virus in patients receiving chemotherapy for no
n-Hodgkin's lymphoma (NHL) may give rise to hepatitis, hepatic failure and
death, and prevent further chemotherapy. We report four patients with NHL i
n whom hepatitis flare-up was observed after two (three patients) and six (
one patient) cycles of chemotherapy. After spontaneous recovery, they were
treated with Lamivudine (100 mg/day), which enabled completion of chemother
apy without. further hepatitis B reactivation. In one patient, high-dose ch
emotherapy and autologous stem cell transplantation was also performed. The
se data suggest a possible role for Lamivudine in preventing hepatitis B re
activation during chemotherapy administration to chronic carriers of the he
patitis B virus. Moreover, it enabled the completion of both standard, and
high-dose chemotherapy in patients with previous hepatitis B reactivation.